 |
|
Bone Mineral Density Response to Estrogen Replacement in Frail Elderly Women
A Randomized Controlled Trial
Dennis T. Villareal, MD;
Ellen F. Binder, MD;
Daniel B. Williams, MD;
Kenneth B. Schechtman, PhD;
Kevin E. Yarasheski, PhD;
Wendy M. Kohrt, PhD
JAMA. 2001;286:815-820.
Context Although hormone replacement therapy (HRT) is an established approach for osteoporosis prevention, little is known about the osteoprotective effects of HRT in frail elderly women.
Objective To determine whether HRT increases bone mineral density (BMD) in frail elderly women.
Design and Setting Randomized, double-blind, placebo-controlled trial conducted in a US university-based research center from September 1995 to August 2000.
Participants Sixty-seven women aged 75 years or older with mild-to-moderate physical frailty.
Intervention Participants were randomly assigned to receive conjugated estrogens, 0.625 mg/d, plus trimonthly medroxyprogesterone acetate, 5 mg/d for 13 days (n = 45), or matching placebo (n = 22), for 9 months.
Main Outcome Measures The primary outcome measure was 9-month change in BMD of the lumbar spine and hip, measured by dual-energy x-ray absorptiometry. Secondary outcomes were changes in markers of bone turnover.
Results Based on intention-to-treat analyses, HRT resulted in significantly larger increases in BMD of the lumbar spine than placebo (mean change, 4.3% vs 0.4%; between-group difference, 3.9%; 95% confidence interval [CI], 3.5%-4.3%) and total hip (mean change, 1.7% vs -0.1%; between-group difference, 1.8%; 95% CI, 1.5%-2.1%). Compared with placebo, HRT resulted in significant decreases in serum bone-specific alkaline phosphatase levels (mean change, -24% vs 6%; between-group difference, -30%; 95% CI, -26% to -33%) and urine N-telopeptide levels (mean change, -48% vs 4%; between-group difference, -52%; 95% CI, -47% to -55%).
Conclusions In physically frail elderly women, 9 months of HRT significantly increased BMD compared with placebo in clinically important skeletal regions. Further studies are needed to determine whether these osteogenic effects of HRT in elderly women are associated with a reduction in osteoporotic fractures.
Author Affiliations: Washington University Claude Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, Department of Internal Medicine (Drs Villareal, Binder, and Yarasheski), Department of Obstetrics and Gynecology (Dr Williams), and Division of Biostatistics (Dr Schechtman), Washington University School of Medicine, St Louis, Mo; and Department of Medicine, Division of Geriatric Medicine, University of Colorado Health Sciences Center, Denver (Dr Kohrt).
RELATED LETTER
Estrogen for Bone Health in Frail Elderly Women
Sharon B. Reed, Michele F. Bellantoni, Dennis T. Villareal, Ellen B. Binder, Daniel B. Williams, Kenneth B. Schechtman, Kevin E. Yarasheski, and Wendy M. Kohrt
JAMA. 2001;286(20):2544.
EXTRACT
| FULL TEXT
RELATED ARTICLE
August 15, 2001
JAMA. 2001;286(7):863-864.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Soy Isoflavones Do Not Affect Bone Resorption in Postmenopausal Women: A Dose-Response Study Using a Novel Approach with 41Ca
Cheong et al.
J. Clin. Endocrinol. Metab. 2007;92:577-582.
ABSTRACT
| FULL TEXT
Treatment and prevention practices in postmenopausal women after bone mineral density screening at a community-based osteoporosis project.
Rohr et al.
JAOA: Journal of the American Osteopathic Association 2006;106:396-401.
ABSTRACT
| FULL TEXT
Effect of Weight Loss and Exercise on Frailty in Obese Older Adults.
Villareal et al.
Arch Intern Med 2006;166:860-866.
ABSTRACT
| FULL TEXT
Phenotype of Frailty: Characterization in the Women's Health and Aging Studies.
Bandeen-Roche et al.
J. Gerontol. A Biol. Sci. Med. Sci. 2006;61:262-266.
ABSTRACT
| FULL TEXT
Clinical Pharmacology of Multiple Doses of Lasofoxifene in Postmenopausal Women
Gardner et al.
J Clin Pharmacol 2006;46:52-58.
ABSTRACT
| FULL TEXT
Venous Thrombosis: The Role of Genes, Environment, and Behavior
Rosendaal
ASH Education Book 2005;2005:1-12.
ABSTRACT
| FULL TEXT
Hormone Replacement Therapy
Lochner and Einhorn
J Am Acad Orthop Surg 2004;12:291-294.
FULL TEXT
Prevalence of Prevention and Treatment Modalities Used in Populations at Risk of Osteoporosis
Rohr et al.
JAOA: Journal of the American Osteopathic Association 2004;104:281-287.
ABSTRACT
| FULL TEXT
Ultralow-Dose Micronized 17{beta}-Estradiol and Bone Density and Bone Metabolism in Older Women: A Randomized Controlled Trial
Prestwood et al.
JAMA 2003;290:1042-1048.
ABSTRACT
| FULL TEXT
Combination Therapy With Hormone Replacement and Alendronate for Prevention of Bone Loss in Elderly Women: A Randomized Controlled Trial
Greenspan et al.
JAMA 2003;289:2525-2533.
ABSTRACT
| FULL TEXT
Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment
Eichner et al.
The Annals of Pharmacotherapy 2003;37:711-724.
ABSTRACT
| FULL TEXT
Risks and benefits of hormone replacement therapy: The evidence speaks
Humphries and Gill
CMAJ 2003;168:1001-1010.
ABSTRACT
| FULL TEXT
Alendronate Prevents Loss of Bone Density Associated With Discontinuation of Hormone Replacement Therapy: A Randomized Controlled Trial
Ascott-Evans et al.
Arch Intern Med 2003;163:789-794.
ABSTRACT
| FULL TEXT
Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)
Hulley et al.
JAMA 2002;288:58-64.
ABSTRACT
| FULL TEXT
Postmenopausal Hormone Therapy and Quality of Life: No Cause for Celebration
Rexrode and Manson
JAMA 2002;287:641-642.
FULL TEXT
Estrogen for Bone Health in Frail Elderly Women
Reed et al.
JAMA 2001;286:2544-2544.
FULL TEXT
Hormone Therapy Helps Combat Osteoporosis in Frail, Elderly Women
JWatch Women's Health 2001;2001:1-1.
FULL TEXT
|
